NRx Pharmaceuticals Deploys First Robotic TMS System for Depression Treatment

Key Facts

1NRx Pharmaceuticals announced its subsidiary HOPE Therapeutics has begun training and deployment of Zeta Surgical's FDA-cleared Zeta TMS Robotic System.

In a move reflecting the accelerating adoption of robotic technologies in the medical sector, NRx Pharmaceuticals announced the deployment of the Zeta TMS Robotic System. According to reports, its subsidiary HOPE Therapeutics has commenced clinical staff training in Florida for the FDA-cleared system developed by Zeta Surgical. This operational milestone aims to leverage robotic precision in Transcranial Magnetic Stimulation (TMS) therapy for treating depression and other psychiatric conditions.

This development comes as clinical-stage biotech firms increasingly integrate AI with medical hardware to improve patient outcomes. The Zeta TMS technology utilizes AI-driven image guidance to track patient movement in real-time, ensuring precise targeting of brain regions identified via MRI. Per market data, NRXP shares closed at $3.40 on September 10, 2026, with the stock trading between a day low of $3.32 and a high of $3.45 during that session.

Investors are watching the success of this initial deployment as a proof-of-concept for HOPE Therapeutics' model in interventional psychiatry. Based on price levels at the close of September 10, 2026, the stock's stability remains a key point of interest for retail traders awaiting clinical results from the robotic system. In the absence of immediate sector-specific catalysts in the upcoming calendar, focus remains on the progress of staff training and the commercial rollout in Florida.